GlassScriptPhysician profile
Jimmy Ruiz
NPI 1265494413
$58,409.38
in general payments reported to CMS, 2019-2025
13 companies · $7,591 in 2025
The $7,591 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $12.45 · 2021: $2,250 · 2022: $2,996 · 2023: $4,358 · 2024: $13K · 2025: $7,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $4,206 · Travel and Lodging: $811 · Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,176.00 |
| Consulting Fee | $4,206.00 |
| Travel and Lodging | $810.50 |
| Food and Beverage | $361.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20,196.33 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $16,001.84 | 2019 | |
| Genentech USA, INC. | $12,431.05 | 2019 | |
| Genzyme Corporation | $3,033.90 | 2022-2023 | |
| Amgen INC. | $2,596.00 | 2023 | |
| Pfizer INC. | $2,250.00 | 2021 | |
| Gilead Sciences, INC. | $1,723.65 | 2023 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $164.16 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jimmy Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.